{"classes":[{"categories":[{"measurements":[{"comment":"Cycle 1 predose is before study drug treatment.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cycle 1 predose is before study drug treatment.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"436"}],"units":"Participants"}],"title":"C1D1/Predose"},{"categories":[{"measurements":[{"comment":"Below the level of detection as expected given the half-life of 13-27 hours per abraxane product label.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Below the level of detection as expected given the half-life of 13-27 hours per abraxane product label.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"C3D1/Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2300","value":"2970"},{"groupId":"OG001","spread":"2050","value":"3080"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"298"}],"units":"Participants"}],"title":"C3D1/ Before End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"244","value":"370"},{"groupId":"OG001","spread":"275","value":"400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"280"}],"units":"Participants"}],"title":"C3D1/Postdose Paclit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"436"}],"units":"Participants"}],"description":"Plasma Concentrations of Total Paclitaxel","dispersionType":"Standard Deviation","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study medication and who have at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Pre-dose (Hour 0) on Cycle 1 Day 1, pre-dose (Hour 0), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after end of nab-paclitaxel infusion (infusion duration = 30 minutes) on Cycle 3 Day 1 (Cycle = 28 days)","title":"Plasma Concentrations of Total Paclitaxel","type":"SECONDARY","unitOfMeasure":"ng/mL"}